Epinastine Hydrochloride Tablets 20mg (Epinastine Hydrochloride Tablets “Sawai”® / エピナスチン塩酸塩錠20mg「サワイ」)

JPY ¥2,500

Japanese Antiallergic Agent (Epinastine Hydrochloride 20mg). Oral tablet for bronchial asthma, allergic rhinitis, urticaria, and pruritic skin conditions, once daily. 100 tablets (10 tablets x 10). Mfd. by Sawai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥2,300
10 - 19 12% JPY ¥2,200
20 + 18% JPY ¥2,050
SKU: EPI-20-TAB Category:

Description

Product Overview / 商品概要

Epinastine Hydrochloride Tablets 20mg (エピナスチン塩酸塩錠20mg「サワイ」)
Generic: Epinastine Hydrochloride / エピナスチン塩酸塩
Therapeutic Category: Antiallergic Agent / アレルギー性疾患治療剤
Manufactured by: Sawai Pharmaceutical Co., Ltd. / 沢井製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Epinastine Hydrochloride 20mg per tablet / 1錠中 エピナスチン塩酸塩 20mg
Additives: Carnauba wax, Titanium dioxide, Magnesium stearate, Talc, Lactose, Hypromellose, Partially pregelatinized starch, Macrogol 6000 / カルナウバロウ、酸化チタン、ステアリン酸Mg、タルク、乳糖、ヒプロメロース、部分アルファー化デンプン、マクロゴール6000
Appearance: Film-coated tablet, white to pale yellow, diameter 8.1mm, thickness 3.6mm, weight approx. 185mg, identification code: SW 132
外観: 剤形: フィルムコーティング錠、性状: 白色~微黄色、直径: 8.1mm、厚さ: 3.6mm、重量: 約185mg、識別コード: SW 132

Indications / 効能効果

EN: Bronchial asthma; Allergic rhinitis; Urticaria, eczema/dermatitis, pruritus cutanea, prurigo, psoriasis vulgaris with pruritus
JA: ○気管支喘息 ○アレルギー性鼻炎 ○蕁麻疹、湿疹・皮膚炎、皮膚瘙痒症、痒疹、瘙痒を伴う尋常性乾癬

Dosage and Administration / 用法用量

EN: For bronchial asthma, urticaria, eczema/dermatitis, pruritus cutanea, prurigo, and psoriasis vulgaris with pruritus: The usual adult dose is 20mg of epinastine hydrochloride orally once daily. Dose may be adjusted according to age and symptoms. For allergic rhinitis: The usual adult dose is 10 to 20mg of epinastine hydrochloride orally once daily. Dose may be adjusted according to age and symptoms.
JA: 〈気管支喘息、蕁麻疹、湿疹・皮膚炎、皮膚瘙痒症、痒疹、瘙痒を伴う尋常性乾癬〉通常、成人にはエピナスチン塩酸塩として1回20mgを1日1回経口投与する。なお、年齢、症状により適宜増減する。〈アレルギー性鼻炎〉通常、成人にはエピナスチン塩酸塩として1回10~20mgを1日1回経口投与する。なお、年齢、症状により適宜増減する。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 22500AMX00370000
Sales Started: July 2002 / 2002年7月
Classification Code: 87449
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 1,000 tablets (10 tablets x 100)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Epinastine Hydrochloride Tablets 20mg (Epinastine Hydrochloride Tablets “Sawai”® / エピナスチン塩酸塩錠20mg「サワイ」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Epinastine Hydrochloride Tablets 20mg (Epinastine Hydrochloride Tablets "Sawai"®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.